Clinical Trial Update: A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports a Phase 1/Phase 2 study of Y101D in combination with gemcitabine and nab-paclitaxel for advanced pancreatic adenocarcinoma, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Abraxane (nab-paclitaxel) (nab-paclitaxel)
• Gemcitabine (Gemcitabine)
• Y101D (PD-L1/TGF-β bispecific antibody)

Snippet

Sponsor: Wuhan YZY Biopharma Co., Ltd. | Conditions: Advanced Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING